Group 1 - The core point of the article is that Nohow Health (06606) will have its listing status canceled by the Hong Kong Stock Exchange effective from October 27, 2025, at 9:00 AM [1] Group 2 - Nohow Health has appointed joint provisional liquidators as part of the process leading to the cancellation of its listing status [1] - The cancellation is in accordance with Listing Rule 6.01A(1) [1]

香港聯合交易所有限公司 (香港交易及結算所有限公司全資附屬公司) THE STOCK EXCHANGE OF HONG KONG LIMITED (A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited) 聯交所宣布，由 2025 年 10 月 27 日上午 9 時起，該公司的上市地位將根據《上市規則》 第 6.01A(1)條予以取消。 該公司的股份自 2024 年 3 月 28 日起已暫停買賣。根據《上市規則》第 6.01A(1)條，若該 公司未能於 2025 年 9 月 27 日或之前復牌，聯交所可將該公司除牌。 該公司未能於 2025 年 9 月 27 日或之前履行聯交所訂下的復牌指引而復牌。於 2025 年 10 月 10 日，上市委員會決定根據《上市規則》第 6.01A(1)條取消該公司股份在聯交所的上市 地位。 聯交所已要求該公司刊發公告，交代其上市地位被取消一事。 聯交所建議，該公司股東如對除牌的影響有任何疑問，應徵詢適當的專業意見。 香港，2025 年 10 月 22 日 通告 關於 諾輝健康（已委任共同臨時清 ...

Core Viewpoint - The article discusses the fraudulent practices of Nohow Health, revealing how the company manipulated sales data and engaged in deceptive activities that led to its impending liquidation and delisting from the stock market [1][23]. Group 1: Fraudulent Practices - Nohow Health was accused of fabricating sales performance, with claims that 90% of its sales revenue was artificially inflated through various deceptive methods, including purchasing fecal samples from sanitation workers [4][8]. - The company utilized a network of third-party firms to facilitate these fraudulent transactions, creating a "virtual sale" environment where actual customer transactions were not necessary [9][11]. - The sales team expanded significantly, from about 100 employees in early 2021 to nearly 500 by 2022, which contributed to a 260% revenue increase, raising sales from 200 million to 760 million [12]. Group 2: Internal Knowledge and Accountability - Key executives, including the company's main leaders, were aware of and led the fraudulent activities, with only a select few high-ranking officials allowed to attend confidential sales strategy meetings [4][16]. - The company attempted to cover up its fraudulent activities by planning to falsify financial reports for 2024, which ultimately led to the withdrawal of Deloitte's audit support [4][18]. Group 3: Market Reaction and Consequences - Following the release of a short-selling report, Nohow Health's stock price plummeted from a peak of 38.95 HKD to 15.7 HKD, with trading volume surging to over 28 million shares on that day [18][19]. - The company is now undergoing a liquidation process, with the board of directors losing actual decision-making power, and the delisting appears inevitable [23]. Group 4: Investor Impact - Over 4,000 individual investors have registered to seek compensation, with total investments exceeding 700 million, highlighting the significant financial impact on public investors [24].

Core Insights - The article discusses the fraudulent practices of Nohui Health, revealing that the company engaged in significant sales performance falsification, leading to severe consequences including stock suspension and management turnover [1][2][10] Group 1: Fraudulent Practices - Nohui Health was found to have fabricated sales performance, employing methods such as purchasing fecal samples from sanitation workers and splitting samples among fake testing accounts [2] - The company's top management was aware of and led the fraudulent activities, with only a few executives allowed to attend confidential sales strategy meetings [2][8] - In 2022, Nohui Health's sales team reported a 260% revenue growth, with sales figures soaring from 200 million to 760 million yuan, despite adverse market conditions [7][10] Group 2: Consequences and Reactions - The release of a short-selling report by CapitalWatch triggered a series of events including Deloitte's refusal to sign off on financials, stock suspension, and the resignation of several executives [1][10] - Nohui Health's attempts to manipulate its financial reports in early 2024 led to Deloitte's withdrawal from the audit process, further exacerbating the company's troubles [2][10] - The company is now facing liquidation proceedings, with a court hearing scheduled for November 14, 2023, and over 4,000 individual investors seeking compensation for their losses [13][10] Group 3: Market Impact - Following the short-selling report, Nohui Health's stock price plummeted from a peak of 38.95 HKD to 15.7 HKD, with trading volume surging to over 28 million shares on the day of the report [10][11] - The fraudulent activities have been acknowledged in legal proceedings, with evidence presented that confirms the systematic nature of the sales fraud [10][12] Group 4: Future Outlook - The founders of Nohui Health have initiated a new venture, indicating a potential shift in focus while the original company faces inevitable delisting and liquidation [12][13] - Investors are left in a precarious position, with individual investors unable to recover their investments while awaiting the outcome of legal investigations [13]

Core Viewpoint - The article discusses the fraudulent practices of Nohui Health, revealing that the company engaged in significant sales data manipulation, leading to its impending liquidation and delisting from the stock market [2][3][12]. Group 1: Fraudulent Practices - Nohui Health was found to have fabricated sales performance, employing methods such as purchasing fecal samples from sanitation workers and splitting samples among fake testing accounts [3]. - The company's top management was aware of and led the fraudulent activities, with only a few executives allowed to attend confidential sales strategy meetings [3]. - In 2022, Nohui Health's sales team reported a 260% revenue growth, with sales figures soaring from 200 million to 760 million yuan, despite adverse conditions like the pandemic [8]. Group 2: Consequences of Fraud - The fraudulent practices led to Deloitte's withdrawal from auditing the company, resulting in a series of negative events including stock suspension and executive resignations [2][3]. - A significant short-selling report by CapitalWatch triggered a dramatic drop in Nohui Health's stock price, from a peak of 38.95 HKD to 15.7 HKD [12][13]. - The company is now in the process of liquidation, with a court hearing scheduled for November 14, where over 4,000 individual investors are seeking compensation for their losses, totaling over 700 million yuan [15][16]. Group 3: Internal Dynamics - The sales team operated under immense pressure to meet targets, leading to a culture of manipulation and risk-taking [9][10]. - Weekly sales meetings were highly confidential, with only select personnel allowed to attend, emphasizing the secretive nature of the operations [9]. - The shift towards compliance in 2023 has led to a restructuring of sales channels, but the legacy of fraudulent practices remains a significant issue for the company [11].

中国经济网北京10月9日讯 近日，平安基金管理有限公司发布关于旗下基金估值调整情况的公告。 公告称，平安基金管理有限公司（以下简称"本公司"）决定自2025年9月30日起，对公司旗下证券 投资基金持有的"诺辉健康"（股票代码：6606.HK）进行估值调整，按照0.01港元/股进行估值。公司将 密切关注上述股票后续经营情况及其他重大事项，进行合理评估，谨慎确定其估值价格。 （责任编辑：康博） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 諾輝健康 | | | | | | 呈交日期: | 2025年10月8日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 06606 | 說明 | 普通股 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.00005 | USD | | 50,000 | | 增加 / 減少 (-) | ...

Group 1 - The first non-surgical targeted drug for treating PFIC, "Bai Er Wei" (generic name: Odevixibat capsules), has been officially launched in China, marking a significant breakthrough in the accessibility of treatment options for PFIC patients [1] - PFIC is a rare genetic disease with an incidence rate of (1-2)/100,000, typically manifesting in newborns or infants under one year old [1] - Odevixibat is the first and only approved non-surgical targeted drug for PFIC in China, which has been included in the domestic and overseas special drug directories of several provinces [1] Group 2 - JD Health's CEO, Jin Enlin, has resigned for family reasons, effective September 29, with a swift appointment of Cao Dong as the new CEO, indicating the company's efficient management response [2] - The resignation of key executives may raise short-term concerns regarding management stability, but the prompt succession plan aims to maintain market confidence [2] Group 3 - Nohui Health, known as the "first stock in cancer early screening," faces delisting risks after being suspended from trading for 18 months due to a short-selling report alleging inflated sales revenue [3] - The company's auditor, Deloitte, refused to endorse its financial statements, leading to the trading suspension, which could severely impact its future business expansion and fundraising efforts [3] Group 4 - Aimeike's subsidiary has received approval for two minoxidil topical solutions (2% and 5%) from the National Medical Products Administration, expanding its product offerings in the hair loss treatment sector [4] - The introduction of these products is expected to create new revenue growth opportunities for Aimeike and enhance its competitive position in the market [4] - This development reflects Aimeike's strength in research and product innovation, which may boost investor confidence and drive stock price appreciation [4]

Core Points - Huatai Fund Management Co., Ltd. announced an adjustment in the valuation of certain funds under its management, specifically regarding the stock of Nohow Health (stock code: 6606.HK) [1] - The valuation adjustment will take effect from September 26, 2025, with the stock being valued at HKD 0.01 per share [1]

（责任编辑：康博） 公告称，创金合信基金管理有限公司经与基金托管人协商一致，自2025年9月26日起，对我司旗下 证券投资基金持有的"诺辉健康（证券代码：6606.HK）"按照0.01港元/股进行估值。 中国经济网北京9月29日讯 近日，创金合信基金管理有限公司发布关于公司旗下部分基金估值调整 情况的公告。 ...